IPCA-LABORATORIES-LTD

About Ipca Laboratories Ltd

Ipca Laboratories Ltd. is a leading Indian pharmaceutical company manufacturing and marketing active pharmaceutical ingredients (APIs) and finished dosage forms. It has a significant presence in branded generics across various therapeutic segments, serving both domestic and international markets, focusing on therapeutic areas like anti-malarials, pain management, and cardiovascular drugs.

Key Financial Ratios of Ipca Laboratories Ltd

• P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Ipca Laboratories Ltd's P/E ratio (TTM) is N/A, compared to the industry median of 32.50 and large cap median of 33.

• P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Ipca Laboratories Ltd's P/B ratio is N/A, compared to the industry median of 4.20 and large cap median of N/A.

• P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Ipca Laboratories Ltd's P/S ratio is 4.14, compared to the industry median of 3.50 and large cap median of N/A.

• PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Ipca Laboratories Ltd's PEG ratio is 4.98.

• EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Ipca Laboratories Ltd's EV/EBITDA ratio is 30.90.

• Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Ipca Laboratories Ltd's ROE is N/A.

• Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Ipca Laboratories Ltd's ROA is N/A.

• Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Ipca Laboratories Ltd's ROCE is N/A.

• Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Ipca Laboratories Ltd's operating margin is N/A.

• Net Margin: Net margin shows what percentage of revenue converts into final net profit. Ipca Laboratories Ltd's net margin is N/A.

• Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Ipca Laboratories Ltd's current ratio is N/A.

• Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Ipca Laboratories Ltd's debt-to-equity ratio is N/A.

• Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Ipca Laboratories Ltd's interest coverage ratio is N/A.

• Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Ipca Laboratories Ltd's DPS is ₹2.

• Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Ipca Laboratories Ltd's EPS is N/A.

(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹N/A. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")

Key Facts

• Founded: 1949

• Headquarters: Mumbai, Maharashtra

• Core Offerings: Active Pharmaceutical Ingredients (APIs), Branded Generics, Finished Dosage Forms, Contract Manufacturing, Nutraceuticals

• Stock Listing: NSE (IPCALAB), BSE (524494)

• Promoter: U.N. Thukral & A.P. Dandikar Family Group

History of Ipca Laboratories Ltd

Ipca Laboratories was incorporated in Mumbai in 1949. In 1975, it was taken over by a new management led by Mr. Premchand Godha, which steered its growth. The company commissioned its first API plant in Ratlam in 1985 and went public in 1994, listing on Indian stock exchanges. Ipca received its first US FDA approval for a finished dosage facility in 2004, solidifying its position as a vertically integrated pharmaceutical company with a strong global footprint.

Business Segments and Revenue Mix

• Formulations: Engages in the manufacturing and marketing of a wide range of finished dosage forms, including tablets, capsules, liquids, and injectables, for various therapeutic areas like pain management, anti-malarials, anti-infectives, cardiology, and dermatology, catering to both domestic and international markets.

• Active Pharmaceutical Ingredients (APIs): Manufactures and supplies APIs for its own formulations and to other pharmaceutical companies globally, with a strong focus on therapeutic segments like anti-malarials (e.g., Chloroquine Phosphate, Hydroxychloroquine Sulfate) and anti-hypertensives.

Key Personnel

Premchand Godha (Chairman & Managing Director): A veteran in the pharmaceutical industry, he has led Ipca's growth and transformation since taking over in 1975, establishing its strong position in APIs and formulations.

Subsidiaries and Associate Companies

• Unichem Laboratories Limited

• Trophic Wellness Pvt. Ltd.

• Ipca Pharmaceuticals Inc. (USA)

Corporate Actions

In 2023-24, Ipca Laboratories acquired a controlling stake (63.35%) in Unichem Laboratories Limited, making it a key subsidiary. Previously, in 2022, the company acquired formulation brands and business from Lyka Labs Ltd.

References

1. Annual Report FY23-24
2. Exchange Filings (NSE/BSE)
3. Financial Results Announcement